Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2019 | Update on selinexor for myeloma and large cell lymphomas

John Kuruvilla • 11 Nov 2019
iwNHL 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma Selinexor

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, Canada, speaking at the 17th International Workshop on Non-Hodgkin Lymphoma, Boston, MA, discusses updates from the trial of selinexor, a first-in-class oral selective inhibitor of nuclear export – the protein XPO1 – in the treatment of multiple myeloma and large cell lymphomas.

More from John Kuruvilla

Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
1:06
Updates on the Phase Ib KEYNOTE-013 trial: pembrolizumab in NHL
John Kuruvilla • 12 Dec 2022
1:18
Hodgkin lymphoma highlights at ASH 2022 and future outlooks
John Kuruvilla • 12 Dec 2022
0:49
Abbv-319: a novel, CD19-GRM antibody-drug conjugate being explored for R/R B-cell malignancies
John Kuruvilla • 12 Dec 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals